Citadel Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.97M | Sell |
1,242,927
-1,514,849
| -55% | -$9.71M | ﹤0.01% | 1538 |
|
|
2025
Q1 | $9.76M | Buy |
2,757,776
+787,072
| +40% | +$2.79M | ﹤0.01% | 1253 |
|
|
2024
Q4 | $7.45M | Buy |
1,970,704
+71,144
| +4% | +$269K | ﹤0.01% | 1499 |
|
|
2024
Q3 | $6.15M | Buy |
1,899,560
+554,742
| +41% | +$1.8M | ﹤0.01% | 1601 |
|
|
2024
Q2 | $2.56M | Buy |
1,344,818
+14,434
| +1% | +$27.4K | ﹤0.01% | 2214 |
|
|
2024
Q1 | $3.78M | Sell |
1,330,384
-910,501
| -41% | -$2.59M | ﹤0.01% | 1974 |
|
|
2023
Q4 | $33M | Buy |
2,240,885
+1,013,941
| +83% | +$14.9M | 0.01% | 636 |
|
|
2023
Q3 | $22.5M | Buy |
1,226,944
+413,619
| +51% | +$7.57M | ﹤0.01% | 745 |
|
|
2023
Q2 | $17.5M | Buy |
813,325
+584,419
| +255% | +$12.6M | ﹤0.01% | 884 |
|
|
2023
Q1 | $6.72M | Buy |
228,906
+172,149
| +303% | +$5.05M | ﹤0.01% | 1589 |
|
|
2022
Q4 | $2.1M | Sell |
56,757
-750,073
| -93% | -$27.7M | ﹤0.01% | 2537 |
|
|
2022
Q3 | $22.7M | Buy |
806,830
+52,420
| +7% | +$1.48M | 0.01% | 752 |
|
|
2022
Q2 | $14.5M | Buy |
754,410
+252,774
| +50% | +$4.87M | ﹤0.01% | 1038 |
|
|
2022
Q1 | $6.45M | Buy |
+501,636
| New | +$6.45M | ﹤0.01% | 1839 |
|